RESUMO
The antidepressant drug vortioxetine has a multimodal action modulating neurotransmission through inhibition of the serotonin transporter and modulation of serotonin receptors. Vortioxetine has also been shown to alleviate cognitive symptoms in preclinical studies and in patients with depression. However, it is largely unclear how vortioxetine affects the brain processing in humans. The present study was conducted in 32 healthy males in a randomized, double-blinded, placebo-controlled, active comparator, four-way crossover design. Treatments were 10 and 20â¯mg/day vortioxetine, 15â¯mg/day escitalopram, and placebo, administered orally once daily for three days. Results were compared to placebo. Treatment effect was assessed by recording spontaneous electroencephalography (EEG) and 40â¯Hz auditory steady state responses. For the spontaneous EEG, both vortioxetine and escitalopram decreased the frequency content in the theta band (4-8â¯Hz) and increased power in the beta (12-32â¯Hz) and gamma (32-45â¯Hz) bands. Vortioxetine and escitalopram decreased connectivity during rest in the theta band and increased connectivity in the gamma bands. Finally, both treatments caused decreased power in the evoked gamma band in response to 40â¯Hz auditory stimulation. Although the global EEG changes were comparable between vortioxetine and escitalopram, subtle differences between treatment effects on the EEG in terms of effect size and regional distribution of the EEG changes were apparent. To our knowledge, the current results are the first data on how vortioxetine affects EEG in humans. The present study calls for further investigations addressing the possible electrophysiological and cognitive effects of vortioxetine.
Assuntos
Encéfalo/efeitos dos fármacos , Encéfalo/fisiologia , Citalopram/farmacologia , Eletroencefalografia/efeitos dos fármacos , Inibidores Seletivos de Recaptação de Serotonina/farmacologia , Vortioxetina/farmacologia , Adulto , Citalopram/sangue , Estudos Cross-Over , Método Duplo-Cego , Eletroencefalografia/métodos , Voluntários Saudáveis , Humanos , Masculino , Pessoa de Meia-Idade , Rede Nervosa/efeitos dos fármacos , Rede Nervosa/fisiologia , Inibidores Seletivos de Recaptação de Serotonina/sangue , Vortioxetina/sangue , Adulto JovemRESUMO
BACKGROUND: The University of California San Diego Performance-based Skills Assessment (UPSA) has been validated as a functional measure in patients with major depressive disorder (MDD). The study herein aims to both replicate and extend the initial validation incorporating data sets from two additional studies. METHODS: NCT02279966 and NCT02272517 were multinational, double-blind, placebo-controlled studies in adult outpatients with moderate-to-severe MDD and a current major depressive episode of ≥3 months and less than 1 year, respectively. Subjects were randomized to vortioxetine (10 or 20â¯mg), placebo or active reference drug (paroxetine [20â¯mg], or escitalopram [10 or 20â¯mg]) for 8 weeks. Pearson correlation coefficients were estimated for baseline UPSA-Brief (UPSA-B), demographic/disease characteristics, Montgomery-Åsberg Depression Rating Scale (MADRS), Perceived Deficit Questionnaire-20 items (PDQ-20), and Digit Symbol Substitution Test (DSST), to examine construct validity. Distribution- and anchor-based methods examined clinically important difference (CID) threshold. A pooled analysis with data from NCT01564862 (initial validation study) was performed to increase the statistical power of the estimations. RESULTS: In pooled analysis of the two new studies, UPSA-B score correlated with the DSST (râ¯=â¯0.32, Pâ¯<â¯0.0001), but not the MADRS (râ¯=â¯-0.07, pâ¯=â¯0.302) or the PDQ-20 (râ¯=â¯-0.10, pâ¯=â¯0.109), replicating initial validation results. Estimated CID range was 7.1-11.2 and 5.5-6.1 points for anchor- and distribution-based methods, respectively. In pooled analyses of all three studies, the CID was 7.0 and 6.4 for anchor- and distribution-based methods, respectively. CONCLUSIONS: These results confirm the construct validity of UPSA for assessing functional capacity in patients with MDD. Estimated CID using UPSA is approximately 6-7 points. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01564862; NCT02272517; NCT02279966.